Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases primarily in North America, Europe, and the Asia Pacific. Its proprietary clinical programs include ARRY-520, a Kinesin spindle protein inhibitor, which is in Phase II clinical trial for patients with multiple myeloma; ARRY-614, a p38/Tie2 dual inhibitor that is in Phase I clinical trial for the treatment of myelodysplastic syndromes; ARRY-797, a p38 inhibitor, which is in Phase II clinical trial for pain; and ARRY-502, a CRTh2 antagonist that is in Phase II clinical trial for asthma. The company’s partnered clinical programs comprise Selumetinib and AZD8330, and MEK162 and MEK300 MEK inhibitors, which are in Phase II clinical trials for the treatment of cancer; Danoprevir, a hepatitis C virus protease inhibitor that is in Phase II trial; AMG 151, a glucokinase activator, which is in Phase II trial for type 2 diabetes; ARRY-543/ASLAN001, a HER2/EGFR inhibitor that is in Phase II clinical trial for gastric cancer; and GDC-0068, a AKT inhibitor, which is in Phase II trial for cancer. Its partnered clinical programs also include LY2603618, a Chk-1 inhibitor that is in Phase II trial for cancer; GDC-0575 and GDC-0425 Chk-1 inhibitors, which are in Phase Ib trial for cancer; ARRY-382, a cFMS inhibitor that is in Phase I trial for cancer; and VTX-2337, a toll-like receptor, which is in Phase Ib trial for cancer. The company has collaborations with Amgen Inc.; ASLAN Pharmaceuticals Pte Ltd.; AstraZeneca, PLC; Celgene Corporation; Genentech Inc.; Novartis International Pharmaceutical Ltd.; Roche Holding AG; Eli Lilly and Company; and VentiRx Pharmaceuticals, Inc. for the development and commercialization of the partnered drugs. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.